Newsroom | 9405 results

WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Priority Review to sNDA for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated NSCLC...

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics reports preclinical data at ASGCT 2026 demonstrating enhanced potency and specificity of engineered CRISPR technologies...

CHARLOTTE, N.C.--(BUSINESS WIRE)--For a second year in a row, Bojangles and The Bojangles Foundation partnered with NFL legend Greg Olsen’s The HEARTest Yard Foundation for a heartwarming “Bojangles Gives from the Heart” initiative. This partnership raised $659,542.54 through sales of the iconic Heart-Shaped Bo-Berry Biscuits® and a guest round-up campaign, exceeding its fundraising goal to support pediatric heart care, family support programs and congenital heart defect research. “This partner...

HERZLIYA, Israel--(BUSINESS WIRE)--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a...

SANTA CLARA, Calif.--(BUSINESS WIRE)--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 millio...

PARIS & DALLAS--(BUSINESS WIRE)--Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company’s first-in-human study. Steve joins Tulyp with more than 30 years of experience in the medical device industry, primarily focused on cardiovascular technologies. He has held leadership roles at Draeger, Medtronic (formerl...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being presented today during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. Ralinepag has not been approved for use in any indication by the U.S. Food and Dr...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the...